Abstract 598TiP
Background
Lung cancer is currently the leading cause of death in cancer patients, non-small cell lung cancer (NSCLC) accounts for 80%-85% and the morbidity is increasing. About 70% of the cases have reached the advanced stage at the time of diagnosis. In some patients, the ECOG performance status (PS) score rates from 2 to 4 with worse prognosis and tolerance. Hence, Prof. Zhou's team defined the concept of "advanced severe lung cancer" in 2017. Currently, most guidelines recommend EGFR-TKIs as first-line treatment for EGFR mutation-positive (19del and L858R) patients. However, PS 2-4 patients were not included in most clinical trials. Thus, the efficacy and safety of EGFR-TKIs for PS 2-4 patients are still unknown in the real world. Aumolertinib is a third-generation EGFR-TKI independently developed in China with lower incidence of adverse events, which may be a better choice for advanced severe lung cancer patients. Thus, this study was designed to explore the efficacy and safety of aumolertinib in the first-line treatment of advanced non-small cell lung cancer patients of PS 3 with EGFR mutations. This may provide valuable hints for clinical applications.
Trial design
A total of 61 patients with EGFR mutations positive (19del and L858R) advanced non-small cell lung cancer with PS 3 will be enrolled and applying Aumolertinib 110 mg PO QD until progression. The primary endpoints are Objective Response Rate (ORR) and the duration of PS improved from 3 at baseline to 1. Secondary endpoints are progression-free survival (PFS), overall survival (OS), quality of life (QoL), disease control rate (DCR) and safety.
Clinical trial identification
NCT05826483.
Legal entity responsible for the study
The First Affiliated Hospital of Guangzhou Medical University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
309P - Expression of estrogen receptor is a negative predictive biomarker for immunotherapy with lenvatinib plus pembrolizumab for advanced endometrial cancer with pMMR
Presenter: Hiroyuki Fujii
Session: Poster Display
Resources:
Abstract
310P - A study on the prediction of recurrence site of endometrial cancer using various machine learning techniques
Presenter: Wonkyo Shin
Session: Poster Display
Resources:
Abstract
311P - Circulating cytokines in the differential diagnosis of endometrial cancer
Presenter: Tatyana Abakumova
Session: Poster Display
Resources:
Abstract
312P - Molecular and genetic features of squamous cell carcinoma of vulvar cancer depending on HPV status
Presenter: Visola Navruzova
Session: Poster Display
Resources:
Abstract
313P - Efficacy and safety of oral metronomic chemotherapy in recurrent refractory advanced gynaecological cancer: Experience from regional cancer center of eastern India
Presenter: Ranti Ghosh
Session: Poster Display
Resources:
Abstract
314P - Perioperative outcomes in advanced epithelial ovarian cancer treated with neoadjuvant bevacizumab and chemotherapy: Real-world experience from an Indian cancer centre
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
315P - Real-world experience of niraparib as maintenance therapy in newly diagnosed advanced ovarian cancer: A single-center retrospective study
Presenter: Wenxin Liu
Session: Poster Display
Resources:
Abstract
316P - First evidence of olaparib maintenance therapy in patients with newly diagnosed BRCA wild-type ovarian cancer: A real-world multicenter study
Presenter: Jing Li
Session: Poster Display
Resources:
Abstract
317P - Attitudes of Israeli gynecologists towards risk reduction salpingo-oophorectomy at hysterectomy for benign conditions and the use of hormonal therapy
Presenter: wisam Assaf
Session: Poster Display
Resources:
Abstract
319P - Survival prediction for ovarian cancer patients from Taiwan cancer registry data
Presenter: Tzu-Pin Lu
Session: Poster Display
Resources:
Abstract